Trial Profile
A Phase 2a A Study of TAC-201 An Cedar pollen Antigen-challenged Study in an Environmental Exposure Chamber
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jun 2016
Price :
$35
*
At a glance
- Drugs TAC 201 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 06 Jun 2016 New trial record